A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT ID: NCT06256328
Last Updated: 2024-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
210 participants
INTERVENTIONAL
2023-12-06
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05144854
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
NCT02267343
Study of ONO-4538 in Gastric Cancer
NCT02746796
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
NCT03006705
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT02872116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ONO-4578+Nivolumab+chemotherapy
ONO-4578
Specified dose, once daily
Oxaliplatin
Specified dose on specified days
Capecitabine
Specified dose on specified days
S-1
Specified dose on specified days
Nivolumab
Specified dose on specified days
placebo+Nivolumab+chemotherapy
Oxaliplatin
Specified dose on specified days
Capecitabine
Specified dose on specified days
S-1
Specified dose on specified days
Nivolumab
Specified dose on specified days
Placebo
Specified dose, once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-4578
Specified dose, once daily
Oxaliplatin
Specified dose on specified days
Capecitabine
Specified dose on specified days
S-1
Specified dose on specified days
Nivolumab
Specified dose on specified days
Placebo
Specified dose, once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients have not been treated with systemic chemotherapy as first-line therapy
* Patients who can provide tumor tissue samples
Exclusion Criteria
* Patients with HER2-positive
* Patients with contraindications to nivolumab, oxaliplatin, S-1, or capecitabine
* Patients who have a history of severe drug-related adverse reactions caused by non- steroidal anti-inflammatory drugs (NSAIDs) or who have complications caused by NSAIDs requiring treatment
* Patients with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease, such as rheumatoid arthritis
* Patients with headache and/or nausea associated with brain metastasis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Project Leader
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
Matsuyama Red Cross Hospital
Matsuyama, Ehime, Japan
NHO Shikoku Cancer Center
Matsuyama, Ehime, Japan
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
NHO Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
JCHO Kyushu Hospital
Yahatanishi-ku, Kitakyusyu-shi, Fukuoka, Japan
Gunma Prefectural Cancer Center
Ota-shi, Gunma, Japan
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Hiroshima, Japan
Hyogo Cancer Center
Akashi-shi, Hyōgo, Japan
JOHAS Kansai Rosai Hospital
Amagasaki-shi, Hyōgo, Japan
Kobe City Hospital Organization Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Ibaraki Prefectural Central Hospital
Kasama-shi, Ibaraki, Japan
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, Japan
Iwate Medical University Hospital
Yahaba-cho, Shiwa-gun, Iwate, Japan
Kagawa University Hospital
Miki-cho, Kita-gun, Kagawa-ken, Japan
Kitasato University Hospital
Sagamihara-shi, Kanagawa, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Osaki Citizen Hospital
Osaki-shi, Miyagi, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Kurashiki Central Hospital
Kurashiki-shi, Okayama-ken, Japan
Osaka International Cancer Institute
Chuo-ku, Osaka, Japan
Kansai Medical University Hospital
Hirakata-shi, Osaka, Japan
Kindai University Hospital
Sayama-shi, Osaka, Japan
Osaka General Medical Center
Sumiyoshi-ku, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki-shi, Osaka, Japan
Saitama Cancer Center
Ina-machi, Kitaadati-gun, Saitama, Japan
Shizuoka Cancer Center
Nagaizumi-cho, Sunto-gun, Shizuoka, Japan
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan
IMSUT Hospital, The Institute of Medical Science, The University of Tokyo
Minato-Ku, Tokyo, Japan
Keio University Hospital
Shinjuku-ku, Tokyo, Japan
Osaka Metropolitan University Hospital
Osaka, , Japan
Kosin University Gospel Hospital
Busan, Gangwon-do, South Korea
Hallym University Sacred Heart Hospital
Anyang-si, Gyeonggi-do, South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Jeonbuk national university hospital
Jeonju, Jeollabuk-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeollanam-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Dong-A University Hospital
Busan, , South Korea
Keimyung University Dongsan Hospital
Daegu, , South Korea
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
Yeungnam University Hospital
Daegu, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Inha University Hospital
Incheon, , South Korea
Asan Medical Center
Seoul, , South Korea
Kangbuk Samsung Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Kyung Hee University Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Chi Mei Hospital, Liouying
Tainan City, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital, Linkou
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-4578-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.